PARIS – Dechert LLP advised Sofinnova Partners in the Series C financing of LimFlow, a developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), for €27 million.

Sofinnova Partners led the financing round with continued participation from existing round B investors Bpifrance and Balestier, and will join the company’s board of directors. The investment is the first for the newly raised Sofinnova Crossover I Fund.

Proceeds from the Series C financing will fund LimFlow's major strategic initiatives through the second half of 2020.

The Paris-based team advising Sofinnova Partners was led by Anne-Charlotte Rivière with assistance from Anne-Sophie Gallot.